BTdCPU is an activator of HRI (heme-regulated eIF2α kinase) with anticancer activity. It can promote eIF2α phosphorylation and induced apoptosis in resistant cells. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Combination therapy with rapamycin, an mTOR inhibitor, and BTdCPU, an activator of HRI, demonstrated additive effects on apoptosis in dex-resistant cells. Thus, specific activation of the eIF2α kinase HRI is a novel therapeutic target in MM that can augment current treatment strategies.

纯度：≥98%

CAS：1257423-87-2